Company profile: Sirona Biochem
1.1 - Company Overview
Company description
- Provider of biotechnology solutions including diabetes therapeutics, cosmetic skin depigmenting and anti-aging agents, biological ingredients and cancer vaccine antigens. Offers compounds such as TFC-1067, LIP-01 and SGLT2 inhibitors, enabled by GlycoMim technology and fluorination chemistry to stabilize carbohydrate-based molecules and enhance pharmaceutical and cosmetic properties.
Products and services
- GlycoMim® technology: Proprietary chemistry architects glycomimetic compounds for pharmaceutical and cosmetic applications, creating carbohydrate-mimicking products tailored to these uses
- Fluorination Chemistry: Industrial-grade chemical process stabilizes carbohydrate molecules, enhancing their pharmaceutical and cosmetic qualities by improving properties of carbohydrate-based molecules
- TFC-1067: Cosmetic-grade skin lightening compound reduces melanin production in the skin, delivering targeted depigmenting action for cosmetic use
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sirona Biochem
Prolong Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical products and development technologies, including PP-007 (Sanguinate), a PEGylated carboxyhemoglobin bovine product designed to deliver oxygen and carbon monoxide to hypoxic tissues to restore homeostasis and reduce inflammation, and PEGfinity, a PEGylation-based process that enhances the function and stability of therapeutic proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prolong Pharmaceuticals company profile →
Regeneron
HQ: United States
Website
- Description: Provider of innovative medicines, including EYLEA for eye diseases (age-related macular degeneration, diabetic retinopathy); Dupixent for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis; REGEN-COV for COVID-19; Libtayo for certain skin cancers and non-small cell lung cancer; Praluent to lower LDL cholesterol; and Kevzara for rheumatoid arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regeneron company profile →
PharmAkea
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D, developing high-quality small molecule drug candidates against protein targets involved in fibroproliferative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmAkea company profile →
Pharmion
HQ: United States
Website
- Description: Provider of products for the treatment of hematology and oncology patients, focused on acquisition, development, and commercialization. Global biotech partnering with scientific and clinical advisors to identify and develop products for hematology and oncology markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmion company profile →
Allegro Ophthalmics
HQ: United States
Website
- Description: Provider of integrin inhibition therapy focused on retinal diseases, including Risuteganib (Luminate), an investigational compound targeting mitochondrial dysfunction and oxidative stress to restore retinal homeostasis for intermediate dry age-related macular degeneration, and ALG-1007, a topical mitochondrial stabilizer in development for dry eye disease with promising clinical trial results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allegro Ophthalmics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sirona Biochem
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sirona Biochem
2.2 - Growth funds investing in similar companies to Sirona Biochem
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sirona Biochem
4.2 - Public trading comparable groups for Sirona Biochem
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →